Tags

Type your tag names separated by a space and hit enter

Evaluation and management of obesity-related nonalcoholic fatty liver disease.
Nat Clin Pract Gastroenterol Hepatol. 2007 Aug; 4(8):432-41.NC

Abstract

The clinicopathologic spectrum of nonalcoholic fatty liver disease (NAFLD) ranges from simple steatosis to nonalcoholic steatohepatitis (NASH). Simple steatosis has a relatively benign clinical course, but NASH can progress to cirrhosis and hepatocellular carcinoma. NAFLD occurs in the absence of significant alcohol use and is considered to be the hepatic manifestation of metabolic syndrome. NAFLD affects approximately 30% of the US population and the incidence seems to be rising as the obesity epidemic continues. At present, the most accurate modality for the diagnosis of NASH is liver biopsy; however, many patients do not have a liver biopsy, and in the absence of more-accurate imaging technologies and serum markers, the diagnosis is frequently one of exclusion. As yet there is no convincingly effective treatment for NAFLD--a multimodal treatment plan that targets obesity, insulin resistance, hyperlipidemia and hypertension might be the best option for these patients.

Authors+Show Affiliations

Inova Fairfax Hospital Annandale, VA 22042, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17667992

Citation

Nugent, Clare, and Zobair M. Younossi. "Evaluation and Management of Obesity-related Nonalcoholic Fatty Liver Disease." Nature Clinical Practice. Gastroenterology & Hepatology, vol. 4, no. 8, 2007, pp. 432-41.
Nugent C, Younossi ZM. Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2007;4(8):432-41.
Nugent, C., & Younossi, Z. M. (2007). Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nature Clinical Practice. Gastroenterology & Hepatology, 4(8), 432-41.
Nugent C, Younossi ZM. Evaluation and Management of Obesity-related Nonalcoholic Fatty Liver Disease. Nat Clin Pract Gastroenterol Hepatol. 2007;4(8):432-41. PubMed PMID: 17667992.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation and management of obesity-related nonalcoholic fatty liver disease. AU - Nugent,Clare, AU - Younossi,Zobair M, PY - 2007/02/21/received PY - 2007/05/17/accepted PY - 2007/8/2/pubmed PY - 2007/9/26/medline PY - 2007/8/2/entrez SP - 432 EP - 41 JF - Nature clinical practice. Gastroenterology & hepatology JO - Nat Clin Pract Gastroenterol Hepatol VL - 4 IS - 8 N2 - The clinicopathologic spectrum of nonalcoholic fatty liver disease (NAFLD) ranges from simple steatosis to nonalcoholic steatohepatitis (NASH). Simple steatosis has a relatively benign clinical course, but NASH can progress to cirrhosis and hepatocellular carcinoma. NAFLD occurs in the absence of significant alcohol use and is considered to be the hepatic manifestation of metabolic syndrome. NAFLD affects approximately 30% of the US population and the incidence seems to be rising as the obesity epidemic continues. At present, the most accurate modality for the diagnosis of NASH is liver biopsy; however, many patients do not have a liver biopsy, and in the absence of more-accurate imaging technologies and serum markers, the diagnosis is frequently one of exclusion. As yet there is no convincingly effective treatment for NAFLD--a multimodal treatment plan that targets obesity, insulin resistance, hyperlipidemia and hypertension might be the best option for these patients. SN - 1743-4386 UR - https://www.unboundmedicine.com/medline/citation/17667992/Evaluation_and_management_of_obesity_related_nonalcoholic_fatty_liver_disease_ L2 - http://dx.doi.org/10.1038/ncpgasthep0879 DB - PRIME DP - Unbound Medicine ER -